Elinore McCance-Katz, MD, PhD, PCSS-B Medical Director
Dr. McCance-Katz has extensive experience with buprenorphine, including clinical use of the medication and research projects aimed at improving clinical care of opioid dependent patients with co-occurring HIV disease and/or Hepatitis C since 1997. She was involved with the development of the original CSAT-sponsored curriculum used to train physicians on this treatment, reviewing CSAT TIP 40 [see "resources" section] which was specifically dedicated to treatment of opioid dependence with buprenorphine. She is the Chair of the AAAP Buprenorphine Treatment Committee, has been responsible for organizing AAAP buprenorphine trainings nationwide, has updated the AAAP web-based and DVD buprenorphine courses, and designed the AAAP Half and Half Course.
John Renner, MD Director, APA Component
Dr. Renner is an Addiction Psychiatrist who has extensive experience with buprenorphine clinically, and has been a national mentor for the PCSS-B program since its beginning. He chairs APA's Council on Adult Psychiatry, as well as its Expert Advisory Panel on Addiction Psychiatry and provides clinical leadership to the association's buprenorphine training initiatives. He is the co-author of Handbook of Office-Based Buprenorphine Treatment of Opioid Dependence. In addition to his contributions to the American Psychiatric Association, Dr. Renner was instrumental in developing AAAP's Half and Half curriculum and is a contributor to the PCSS-B's complex case series.
Stephen Wyatt, DO Director, AOAAM Component
Upon completion of Dr. Wyatt's psychiatry residency in 1996, he became a NIDA Clinical Research Fellow in the Department of Psychiatry at the Yale School of Medicine. He has worked extensively with patients with co-occurring disorders utilizing buprenorphine. He has an active buprenorphine practice where he treats patients with opioid dependence as well as chronic pain and opioid addiction.w, Dr. Wyatt also teaches addiction medicine in a variety of venues.